ArticleCureus2023
Superficial CD34-Positive Fibroblastic Tumor: A Newly Recognized Entity With Overlapping Features of PRDM10-Rearranged Soft Tissue Tumors.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superficial CD34-positive fibroblastic tumor (SCPFT) is a recently identified, infrequent, low-grade mesenchymal neoplasm, first identified in 2014. Although it is relatively new to the field, SCPFT has been gaining prominence in surgical pathology practice because of its distinctive features. As of now, there are limited reported cases of SCPFT, with fewer than 100 instances documented in scientific literature. This distinctive blend of rarity and intriguing variability in presentation emphasizes the significance of identifying and understanding this uncommon entity, facilitating precise diagnosis and optimal management. In this article, we aimed to present a notable case of SCPFT in a male in his 20s who presented with a distinct subcutaneous mass measuring 2.4 × 1.8 cm at the medial aspect of the knee joint. The patient reported no significant medical history or trauma to the affected area. MRI of the knee showed a well-defined 2.4 × 1.8 cm subcutaneous mass with no definite communication with the underlying ligament or meniscus. The histopathological examination revealed spindle cell neoplasm arranged in intersecting fascicles, accompanied by arborizing blood vessels. Neoplastic spindle cells exhibited marked nuclear pleomorphism, and abundant and eosinophilic cytoplasm, with focal areas of granular, glassy, and lipidized cytoplasm. Nuclear pseudo inclusions and a few mitotic figures (1-2 per high-power field) were noted. Inflammatory infiltrates were identified within the neoplasm, comprising eosinophils and lymphocytes, highlighting an immune response within the tumor microenvironment. The surgical margin exhibited involvement with the tumor infiltrates, with the neoplastic cells extending into the adjacent fat tissue. This finding indicates local tumor spread and potential challenges in achieving complete resection. Immunohistochemical staining showed positive staining for CD34, corroborating the diagnosis of a CD34-positive fibroblastic tumor. Focal positive staining for pan-CK was noted. Staining for CD31, smooth muscle actin (SMA), desmin, S100, and anaplastic lymphoma kinase (ALK) was negative, supporting the diagnosis. The Ki67 proliferation index was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.